Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01562041 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01562041 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT01562041, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).
Interventions
- DRUG Ranolazine 500 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03-09 |
| Est. Completion | 2014-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01562041
The ClinicalTrials.gov registry entry for NCT01562041 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine 500 mg is the first listed.
NCT01562041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01562041 about?
NCT01562041 is a clinical study titled "Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease". The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).
What is the current status of trial NCT01562041?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-03-09. Estimated completion is 2014-01-02.
What interventions are being tested in trial NCT01562041?
The interventions under investigation include: Ranolazine 500 mg (DRUG).
Who is sponsoring clinical trial NCT01562041?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.